Abstract
Fibrosis is part of airway remodelling observed in bronchial asthma and COPD. Pro-fibrotic activity of lung fibroblasts may be suppressed by β-adrenoceptor activation. We aimed, first, to characterise the expression pattern of β-adrenoceptor subtypes in human lung fibroblasts and, second, to probe β-adrenoceptor signalling with an emphasis on anti-fibrotic actions. Using reverse transcription PCR, messenger RNA (mRNA) encoding β2-adrenoceptors was detected in MRC-5, HEL-299 and primary human lung fibroblasts, whereas transcripts for β1- and β3-adrenoceptors were not found. Real-time measurement of dynamic mass redistribution in MRC-5 cells revealed β-agonist-induced Gs-signalling. Proliferation of MRC-5 cells (determined by [3H]-thymidine incorporation) was significantly inhibited by β-agonists including the β2-selective agonist formoterol (−logIC50, 10.2) and olodaterol (−logIC50, 10.6). Formoterol’s effect was insensitive to β1-antagonism (GCP 20712, 3 μM), but sensitive to β2-antagonism (ICI 118,551; apparent, pA 2, 9.6). Collagen synthesis in MRC-5 cells (determined by [3H]-proline incorporation) was inhibited by β-agonists including formoterol (−logIC50, 10.0) and olodaterol (−logIC50, 10.3) in a β2-blocker-sensitive manner. α-Smooth muscle actin, a marker of myo-fibroblast differentiation, was down-regulated at the mRNA and the protein level by about 50% following 24 and 48 h exposure to 1 nM formoterol, a maximally active concentration. In conclusion, human lung fibroblasts exclusively express β2-adrenoceptors and these mediate inhibition of various markers of pro-fibrotic cellular activity. Under clinical conditions, anti-fibrotic actions may accompany the therapeutic effect of long-term β2-agonist treatment of bronchial asthma and COPD.
Similar content being viewed by others
References
Antony J, Kellershohn K, Mohr-Andrä M, Kebig A, Prilla S, Muth M, Heller E, Disingrini T, Dallanoce C, Bertoni S, Schrobang J, Tränkle C, Kostenis E, Christopoulos A, Höltje HD, Barocelli E, De Amici M, Holzgrabe U, Mohr K (2009) Dualsteric GPCR targeting: a novel route to binding and signaling pathway selectivity. FASEB J 23:442–450
Baker JG (2005) The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors. Br J Pharmacol 144:317–322
Baouz S, Giron-Michel J, Azzarone B, Giuliani M, Cagnoni F, Olsson S, Testi R, Gabbiani G, Canonica GW (2005) Lung myofibroblasts as targets of salmeterol and fluticasone propionate: inhibition of alpha-SMA and NF-kappaB. Int Immunol 17:1473–1481
Barnes PJ (2004) The role of anticholinergics in chronic obstructive pulmonary disease. Am J Med 20(117 Suppl 12A):24S–32S
Baum BJ, Moss J, Breul SD, Crystal RG (1978) Association in normal human fibroblasts of elevated levels of adenosine 3′:5′-monophosphate with a selective decrease in collagen production. J Biol Chem 253:3391–3394
Bond RA, Leff P, Johnson TD, Milano CA, Rockman HA, McMinn TR, Apparsundaram S, Hyek MF, Kenakin TP, Allen LF et al (1995) Physiological effects of inverse agonists in transgenic mice with myocardial overexpression of the beta 2-adrenoceptor. Nature 16(374):272–276
Bos JL (2006) Epac proteins: multi-purpose cAMP targets. Trends Biochem Sci 31:680–686
Bouyssou T, Casarosa P, Naline E, Pestel S, Konetzki I, Devillier P, Schnapp A (2010) Pharmacological characterization of olodaterol, a novel inhaled beta2-adrenoceptor agonist exerting a 24-hour-long duration of action in preclinical models. J Pharmacol Exp Ther 334:53–62
Brewster CE, Howarth PH, Djukanovic R, Wilson J, Holgate ST, Roche WR (1990) Myofibroblasts and subepithelial fibrosis in bronchial asthma. Am J Respir Cell Mol Biol 3:507–511
Chiappara G, Gagliardo R, Siena A, Bonsignore MR, Bousquet J, Bonsignore G, Vignola AM (2001) Airway remodelling in the pathogenesis of asthma. Curr Opin Allergy Clin Immunol 1:85–93
Davies DE, Wicks J, Powell RM, Puddicombe SM, Holgate ST (2003) Airway remodeling in asthma: new insights. J Allergy Clin Immunol 111:215–225
de Rooij J, Zwartkruis FJ, Verheijen MH, Cool RH, Nijman SM, Wittinghofer A, Bos JL (1998) Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP. Nature 396:474–477
Fitzgerald MF, Fox JC (2007) Emerging trends in the therapy of COPD: bronchodilators as mono- and combination therapies. Drug Discov Today 12:472–478
Freitag A, Reimann A, Wessler I, Racké K (1996) Effects of bacterial lipopolysaccharides (LPS) and tumor necrosis factor-α (TNF-α) on rat tracheal epithelial cells in culture: morphology, proliferation and induction of NO synthase. Pulm Pharmacol 9:149–156
Furchgott RF (1972) The classification of adrenoceptors (adrenergic receptors). An evaluation from the standpoint of receptor theory. In: Blaschko H, Muscholl E (eds) Handbook experimental pharmacology, vol 33. Springer, Berlin, pp 283–335
Goulet S, Bihl MP, Gambazzi F, Tamm M, Roth M (2007) Opposite effect of corticosteroids and long-acting beta(2)-agonists on serum- and TGF-beta(1)-induced extracellular matrix deposition by primary human lung fibroblasts. J Cell Physiol 210:167–176
Haag S, Matthiesen S, Juergens UR, Racké K (2008a) Muscarinic receptors mediate stimulation of collagen synthesis in human lung fibroblasts. Eur Resp J 32:555–562
Haag S, Warnken M, Juergens UR, Racké K (2008b) Role of Epac1 in mediating anti-proliferative effects of prostanoid EP2 receptors and cAMP in human lung fibroblasts. Naunyn Schmiedeberg’s Arch Pharmacol 378:617–630
Hogg JC (2004) Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet 364:709–721
Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, Cherniack RM, Rogers RM, Sciurba FC, Coxson HO, Pare PD (2004) The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 350:2645–2653
Holgate ST (2002) Airway inflammation and remodeling in asthma: current concepts. Mol Biotechnol 22:179–189
Holz GG, Chepurny OG, Schwede F (2008) Epac-selective cAMP analogs: New tools with which to evaluate the signal transduction properties of cAMP-regulated guanine nucleotide exchange factors. Cell Signal 20:10–20
Huang S, Wettlaufer SH, Hogaboam C, Aronoff DM, Peters-Golden M (2007) Prostaglandin E(2) inhibits collagen expression and proliferation in patient-derived normal lung fibroblasts via E prostanoid 2 receptor and cAMP signaling. Am J Physiol Lung Cell Mol Physiol 292:L405–L413
Huang S, Scott H, Wettlaufer SH, Peters-Golden M (2008) Prostaglandin E2 inhibits specific lung fibroblast functions via selective actions of PKA and Eapc-1. Am J Respir Cell Mol Biol 39:482–489
Jeffery PK (2001) Remodeling in asthma and chronic obstructive lung disease. Am J Respir Crit Care Med 164:S28–S38
Jeffery PK (2004) Remodeling and inflammation of bronchi in asthma and chronic obstructive pulmonary disease. Proc Am Thorac Soc 1:176–183
Kawasakia H, Springett GM, Mochizuki N, Toki S, Nakaya M, Matsuda M, Housman DE, Graybiel AM (1998) A family of cAMP-binding proteins that directly activate Rap1. Science 282:2275–2279
Kebig A, Kostenis E, Mohr K, Mohr-Andrä M (2009) An optical dynamic mass redistribution assay reveals biased signaling of dualsteric GPCR activators. J Recept Signal Transduct Res 29:140–145
Liu X, Ostrom RS, Insel PA (2004) cAMP-elevating agents and adenylyl cyclase overexpression promote an antifibrotic phenotype in pulmonary fibroblasts. Am J Physiol Cell Physiol 286:C1089–C1099
Matthiesen S, Bahulayan A, Kempens S, Haag S, Fuhrmann M, Stichnote C, Juergens UR, Racké K (2006) Muscarinic receptor mediate stimulation of human lung fibroblast proliferation. Am J Resp Cell Mol Biol 35:621–627
Matthiesen S, Bahulayan A, Holz RK (2007) MAPK pathway mediates muscarinic receptor-induced human lung fibroblast proliferation. Life Sci 80:2259–2262
Molfino NA, Jeffery PK (2007) Chronic obstructive pulmonary disease: histopathology, inflammation and potential therapies. Pulm Pharmacol Ther 20:462–472
Peterkofsky B, Diegelmann R (1971) Use of a mixture of proteinase-free collagenases for the specific assay of radioactive collagen in the presence of other proteins. Biochemistry 10:988–994
Racké K, Haag S, Bahulayan A, Warnken M (2008) Pulmonary fibroblasts, an emerging target for anti-obstructive drugs. Naunyn Schmiedeberg’s Arch Pharmacol 378:193–201
Roche WR, Beasley R, Williams JH, Holgate ST (1989) Subepithelial fibrosis in the bronchi of asthmatics. Lancet 1(8637):520–524
Roscioni SS, Dekkers BGJ, Prins AG, Menzen MH, Meurs H, Schmidt M, Maarsingh H (2011a) cAMP inhibits modulation of airway smooth muscle phenotype via the exchange protein activated by cAMP (Epac) and protein kinase A. Br J Pharmacol 162:193–209
Roscioni SS, Prins AG, Elzinga CR, Menzen MH, Dekkers BG, Halayko AJ, Meurs H, Maarsingh H, Schmidt M (2011b) Functional roles of Epac and PKA in human airway smooth muscle phenotype plasticity. Br J Pharmacol. doi:10.1111/j.1476-5381.2011.01354.x
Schröder R, Merten N, Mathiesen JM, Martini L, Kruljac-Letunic A, Krop F, Blaukat A, Fang Y, Tran E, Ulven T, Drewke C, Whistler J, Pardo L, Gomeza J, Kostenis E (2009) The C-terminal tail of CRTH2 is a key molecular determinant that constrains Gαi and downstream signaling cascade activation. J Biol Chem 284:1324–1336
Schröder R, Janssen N, Schmidt J, Kebig A, Merten N, Hennen S, Müller A, Blättermann S, Mohr-Andrä M, Zahn S, Wenzel J, Smith NJ, Gomeza J, Drewke C, Milligan G, Mohr K, Kostenis E (2010) Deconvolution of complex G protein-coupled receptor signaling in live cells using dynamic mass redistribution measurements. Nat Biotechnol 28:943–949
Silvestri M, Fregonese L, Sabatini F, Dasic G, Rossi GA (2001) Fluticasone and salmeterol downregulate in vitro, fibroblast proliferation and ICAM-1 or H-CAM expression. Eur Respir J 18:139–145
Sin DD, McAlister FA, Man SF, Anthonisen NR (2003) Contemporary management of chronic obstructive pulmonary disease: scientific review. JAMA 290:2301–2312
Skålhegg BS, Taskén K (2000) Specificity in the cAMP/PKA signaling pathway. Differential expression, regulation, and subcellular localization of subunits of PKA. Front Biosci 5:D678–D693
Smith C, Teitler M (1999) Beta-blocker selectivity at cloned human beta 1- and beta 2-adrenergic receptors. Cardiovasc Drugs Ther 13:123–126
Spoelstra FM, Postma DS, Hovenga H, Noordhoek JA, Kauffman HF (2000) Budesonide and formoterol inhibit ICAM-1 and VCAM-1 expression of human lung fibroblasts. Eur Respir J 15:68–74
Spoelstra FM, Postma DS, Hovenga H, Noordhoek JA, Kauffman HF (2002) Additive anti-inflammatory effect of formoterol and budesonide on human lung fibroblasts. Thorax 57:237–241
Todorova L, Gürcan E, Miller-Larsson A, Westergren-Thorsson G (2006) Lung fibroblast proteoglycan production induced by serum is inhibited by budesonide and formoterol. Am J Respir Cell Mol Biol 34:92–100
Walters JA, Wood-Baker R, Walters EH (2005) Long-acting beta2-agonists in asthma: an overview of Cochrane systematic reviews. Respir Med 99:384–395
Ward C, Pais M, Bish R, Reid D, Feltis B, Johns D, Walters EH (2002) Airway inflammation, basement membrane thickening and bronchial hyperresponsiveness in asthma. Thorax 57:309–316
Westergren-Thorsson G, Larsen K, Nihlberg K, Andersson-Sjöland A, Hallgren O, Marko-Varga G, Bjermer L (2010) Pathological airway remodelling in inflammation. Clin Respir J 4(Suppl 1):1–8
Wilson JW, Bamford TL (2001) Assessing the evidence for remodelling of the airway in asthma. Pulm Pharmacol Ther 14:229–247
Acknowledgement
This work was supported by Research Grants from AstraZeneca, Boehringer Ingelheim and Bonfor, University of Bonn. The paper contains part of the Ph.D. thesis of FL and ASA. We thank M. Fuhrmann for excellent technical assistance. W.K.S. was supported by the NRW International Graduate Research School BIOTECH-PHARMA.
Author information
Authors and Affiliations
Corresponding author
Additional information
F. Lamyel and M. Warnken-Uhlich contributed equally to this work.
Rights and permissions
About this article
Cite this article
Lamyel, F., Warnken-Uhlich, M., Seemann, W.K. et al. The β2-subtype of adrenoceptors mediates inhibition of pro-fibrotic events in human lung fibroblasts. Naunyn-Schmiedeberg's Arch Pharmacol 384, 133–145 (2011). https://doi.org/10.1007/s00210-011-0655-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00210-011-0655-5